Close

Surfarray™ Cell Microarray Technology

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Cell microarray technology is a powerful tool for the discovery of human cell surface and secretory protein targets for various antibodies, proteins, and small molecules. This method can process thousands of units simultaneously. By doing so, a global map of cellular functions can be generated.

Creative Biolabs' unique and highly sensitive Surfarray™ cell microarray technology allows us to provide fast, accurate and efficient solutions to our customers around the world:

  • Discover novel, high quality, and developable cell therapy targets
  • Detect specific interactions with a high degree of sensitivity
  • Widely covered known plasma membranes and secreted protein subclasses
  • Explore safety liability of lead candidates

Key Applications of Cell Microarray Technology

Cell-based microarrays can be used in different applications. Our case studies focus on providing more details on receptor identification, targeted deconvolution, and specific screening of biotherapeutics such as CAR-T cells and antibodies.

Target Deconvolution

Target Deconvolution

Cellular microarray technology is well suited for target deconvolution. It ranges from the primary targets of revealing antibodies or small molecule compounds identified by phenotypic screening to commercially available drugs. Our microarray technology is widely used for CAR-T and antibody target deconvolution:

  • Discover novel, pharmaceutically acceptable targets
  • Receptor molecules are targeted by phenotypic molecules (antibodies, scFvs, Fc-fusion proteins, etc.)
  • Identification of disease-specific antigens by screening patient sera
Receptor Identification

Receptor Identification

Our cell microarrays are optimized for the identification of physiologically relevant cell surface interactions. It recognizes cell surface receptors and secreted targets of a wide range of molecules ranging from purified proteins to more complex ligands such as whole cells:

  • Natural soluble proteins and peptides
  • Live virus and virus-like particles (VLPs)
  • Cell surface derived ligand
  • Whole cell expressing the ligand of interest
  • Plasma sample from patient
Novel Immune Checkpoints Discovery

Novel Immune Checkpoints Discovery

Identifying new immune checkpoint therapeutic targets provides important business value to our customers. Since many important immune checkpoint interactions have not been fully characterized, we use cell microarray technology to identify immunological checkpoint targets with high specificity.

Contact us to learn about case studies and we'll show you how to use cell microarray technology to identify immune checkpoint targets with high specificity.

Off-Target Profiling

Off-Target Profiling

Our off-target analysis is used to assess off-targets of plasma membranes and secreted proteins expressed in human cells. Highlights:

  • Has a very low false positive/negative number
  • Can predict/interpret reduced bioavailability due to off-target binding
  • Can inform pre-clinical tox model selection, reduce animal testing

Off-targets include:

  • Antibodies & bispecifics
  • ScFvs, Fabs or antibody derivatives
  • Peptides
  • Protein ligands
  • Labelled small molecules
CAR-T Cells Specificity Screening

CAR-T Cells Specificity Screening

Our cell microarray technology can label and screen entire CAR-T cells and is widely used to evaluate final engineered cells as well as precursor antibodies/scFv. There are two methods for targeted screening of CAR-T cells:

  • Screening antigen recognition elements - scFv
  • Screening of engineered CAR-T cells

Early specific screening helps to select the right scFv to maximize the chances of producing the most promising potential CAR-T therapy. A more relevant assessment of off-target responsibility can then be provided by screening the entire engineered T cell (or final scFv).

CAR Specificity Screening and Profiling with High-throughput Membrane Protein Array

CAR Specificity Screening and Profiling with High-throughput Membrane Protein Array

We developed a cell-based high-throughput membrane protein array for CAR specificity screening and profiling. The analytical data aids in determining CAR target specificity, excluding scFv with a cross response, and forecasting the side effects of the CAR's proposed uses. This platform can be used for:

  • Investigating whether the intended target is recognized;
  • Profiling the positive binding of CAR in human membrane proteins;
  • Providing information on the number, identities, and strength of cross-reaction.

Creative Biolabs is dedicated to helping our worldwide customers shorten the discovery and development time in CAR-T cell therapy. We utilize unrivaled, proprietary drug design, study data, product candidate, advanced project life-cycle management, as well as real-time data to ensure the ideal outcomes.

For more detailed information, please feel free to contact us or directly send us an inquiry.

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.